Dasabuvir (trade name Exviera) and the fixed-dose drug combination ombitasvir/paritaprevir/ritonavir (trade name Viekirax) have been available since January 2015 for the treatment of adults with chronic hepatitis C infection. ...
Aug 6, 2015
0
9
(HealthDay)—Technivie (ombitasvir, paritaprevir and ritonavir) has been approved by the U.S. Food and Drug Administration, in tandem with ribavirin, to treat hepatitis C genotype 4 infection among people without cirrhosis ...
Jul 25, 2015
0
21
Researchers have found that using a combination of sofosbuvir and a new drug agent known as daclastasvir is highly successful in treating co-infected hepatitis C (HCV) and HIV patients.
Jul 22, 2015
0
36
Researchers from Ludwig-Maximilians-Universitaet (LMU) in Munich have demonstrated, in a preclinical setting, the protective effect of a candidate vaccine directed against the coronavirus that causes Middle East Respiratory ...
Jun 22, 2015
0
19
In two studies appearing in the May 5 issue of JAMA, patients with chronic hepatitis C virus (HCV) genotype 1 infection and with or without cirrhosis achieved high rates of sustained virologic response after 12 weeks of treatment ...
May 5, 2015
0
20
A new study revealed today at The International Liver Congress 2015 shows that sofosbuvir (SOF)-based regimens are effective and well tolerated in hepatitis C and HIV co-infected, cirrhotic patients. Sustained virologic response ...
Apr 23, 2015
0
2
Interim data presented today at The International Liver Congress 2015 from the HCV-TARGET study show that all-oral, direct-acting antiviral therapy for hepatitis C (HCV) is well tolerated and highly effective in patients ...
Apr 23, 2015
0
2
(HealthDay)—For patients with hepatitis C virus (HCV), statin therapy is associated with improved virologic response rates, as well as decreased liver fibrosis progression and hepatocellular carcinoma (HCC) incidence, according ...
Apr 10, 2015
0
63
Patients with chronic hepatitis C virus infection and advanced fibrosis or cirrhosis who attained sustained virological response (SVR) had survival comparable with that of the general population, whereas patients who did ...
Nov 11, 2014
0
0
With a $40,250 grant from the Lottie Caroline Hardy Charitable Trust Fund, researchers at Saint Louis University's Institute for Molecular Virology will study a small fragment of adenovirus as a possible future therapy for ...
May 23, 2014
0
0
